TW200416044A - Humanized anti-lymphotoxin β receptor antibodies - Google Patents

Humanized anti-lymphotoxin β receptor antibodies Download PDF

Info

Publication number
TW200416044A
TW200416044A TW092117964A TW92117964A TW200416044A TW 200416044 A TW200416044 A TW 200416044A TW 092117964 A TW092117964 A TW 092117964A TW 92117964 A TW92117964 A TW 92117964A TW 200416044 A TW200416044 A TW 200416044A
Authority
TW
Taiwan
Prior art keywords
antibody
ser
thr
val
gly
Prior art date
Application number
TW092117964A
Other languages
English (en)
Chinese (zh)
Inventor
Ellen Garber
Kenneth Simon
Jose W Saldanha
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of TW200416044A publication Critical patent/TW200416044A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW092117964A 2002-07-01 2003-07-01 Humanized anti-lymphotoxin β receptor antibodies TW200416044A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39299302P 2002-07-01 2002-07-01
US41737202P 2002-10-09 2002-10-09

Publications (1)

Publication Number Publication Date
TW200416044A true TW200416044A (en) 2004-09-01

Family

ID=30003289

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092117964A TW200416044A (en) 2002-07-01 2003-07-01 Humanized anti-lymphotoxin β receptor antibodies

Country Status (10)

Country Link
US (1) US7429645B2 (https=)
EP (1) EP1539793A4 (https=)
JP (1) JP2005532051A (https=)
CN (1) CN1678625A (https=)
AR (1) AR040367A1 (https=)
AU (1) AU2003248782A1 (https=)
CA (1) CA2491480A1 (https=)
NZ (1) NZ537965A (https=)
TW (1) TW200416044A (https=)
WO (1) WO2004002431A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CZ20011272A3 (cs) * 1998-10-09 2001-09-12 Biogen, Inc. Použití činidla, které blokuje vazbu lymfotoxinu-beta na jeho receptor, pro výrobu protivirového léku
PL366307A1 (en) * 2000-10-13 2005-01-24 Biogen, Inc. Humanized anti-lt-beta-r antibodies
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
WO2004058183A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
NZ544924A (en) * 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
JP2005241389A (ja) * 2004-02-25 2005-09-08 Ochiyanomizu Jiyoshi Univ 蛍光標識糖鎖の特異的固定化試薬および固定化方法
KR20060132006A (ko) * 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
UA94484C2 (uk) 2006-10-12 2011-05-10 Дженентек, Інк. Антитіла до лімфотоксину-альфа
CN101600450A (zh) * 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
BRPI0813645A2 (pt) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
JP2012514458A (ja) * 2008-12-31 2012-06-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗リンホトキシン抗体
RU2012153241A (ru) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
TWI897855B (zh) * 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
CA3164226A1 (en) 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CR20240246A (es) * 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
KR20260036556A (ko) 2023-07-07 2026-03-17 메스태그 테라퓨틱스 리미티드 결합 작제물
EP4527851A1 (en) 2023-09-22 2025-03-26 Bayer Aktiengesellschaft Bispecific antibodies binding ltbr and lrrc15
WO2025172587A1 (en) 2024-02-16 2025-08-21 Mestag Therapeutics Ltd Binding constructs
WO2025172588A1 (en) 2024-02-16 2025-08-21 Mestag Therapeutics Ltd Bispecific constructs directed against fap and ltbr
WO2025221728A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH06501456A (ja) 1990-06-27 1994-02-17 バイオジェン，インコーポレイテッド 表面複合リンホトキシン
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2150249A1 (en) 1992-12-04 1994-06-23 Jeffrey Browning Lymphotoxin-.beta., lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
KR100475492B1 (ko) * 1995-01-26 2005-03-14 바이오겐 아이덱 엠에이 인코포레이티드 항종양제로서의 림프독소-α/β 복합체 및항-림프독소-β수용체 항체
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2319698A1 (en) 1998-01-30 1999-08-05 Biogen, Inc. Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
PL366307A1 (en) * 2000-10-13 2005-01-24 Biogen, Inc. Humanized anti-lt-beta-r antibodies
WO2004058183A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
KR20060132006A (ko) * 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도

Also Published As

Publication number Publication date
NZ537965A (en) 2008-04-30
JP2005532051A (ja) 2005-10-27
EP1539793A4 (en) 2006-02-01
CN1678625A (zh) 2005-10-05
AU2003248782A1 (en) 2004-01-19
CA2491480A1 (en) 2004-01-08
WO2004002431A3 (en) 2004-08-26
WO2004002431A2 (en) 2004-01-08
US7429645B2 (en) 2008-09-30
EP1539793A2 (en) 2005-06-15
US20060222644A1 (en) 2006-10-05
AR040367A1 (es) 2005-03-30

Similar Documents

Publication Publication Date Title
TW200416044A (en) Humanized anti-lymphotoxin β receptor antibodies
JP5894912B2 (ja) 抗ヒトｃｄ５２免疫グロブリン
AU2002211747B2 (en) Humanized anti-LT-Beta-R antibodies
TWI592425B (zh) 與ｃｘｃｒ４結合之人抗體及彼之用途
CN108699157B (zh) Psma结合抗体及其用途
AU2021273240B2 (en) Anti-tigit antibody and preparation method and application thereof
US20090155255A1 (en) Cd23 binding molecules and methods of use thereof
JP2009298818A (ja) インターフェロンα受容体（ＩＦＮＡＲ−１）に対するヒト化抗体
CN109069622A (zh) 特异性结合人cd40的拮抗性抗体和使用方法
TW200817437A (en) Monoclonal antibodies against stromal cell derived factor-1 (SDF-1)
TW201132356A (en) Antagonist anti-IL-7 receptor antibodies and methods
JP7048567B2 (ja) 二重特異性抗原結合ポリペプチド
CN101137673A (zh) Cripto结合分子
TW200823237A (en) Antibodies to NTB-A
CN109071655A (zh) 具有增强的激动剂活性的cd40的抗体
CN116096753A (zh) 对abcb5具有特异性的抗体及其用途
WO2018152687A1 (en) Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof
WO2023241656A1 (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
EP3623383A1 (en) Improved bispecific flt3xcd3 antigen binding proteins
CA3111462C (en) Improved anti-flt3 antigen binding proteins
CA3111462A1 (en) Improved anti-flt3 antigen binding proteins